Market Overview

Investor Ideas: Biotech/ Pharma Stock Trading News Alert: Affymax Trades Up 37% on FDA Advisory Committee Vote


POINT ROBERTS, December 8, 2011 -, a global investor research portal for independent investors, issues a trading alert for Biotech/Pharma stock, Affymax, Inc. (NasdaqGS: AFFY) trading at $8.06, up 2.20 (37.50%) 2:09PM EST. The stock has a high of $8.45 in today's trading session.

Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 15 to 1, with 1 abstention, that peginesatide demonstrated a favorable benefit/risk profile for use in the treatment of dialysis patients with anemia due to chronic kidney disease (CKD).

About is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Follow on Twitter!/Investorideas

Follow on Facebook

Research and trade biotech and pharma stocks with the global stock directory :

Visit our biotech stocks research page:

Investor Research Tools;

Get Free investor news and stock alerts

Sign Up:

Join Investor Ideas

Get 13 of the best stock directories online and investing ideas and stock alerts

Research biotech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more. Join:

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising .


Source -

The preceding article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.


Related Articles (AFFY)

View Comments and Join the Discussion!

Posted-In: investments pharma stocksBiotech Markets